Exane Derivatives’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $232K | Sell |
1,517
-1,221
| -45% | -$187K | 0.13% | 147 |
|
|
2022
Q1 | $444K | Sell |
2,738
-527
| -16% | -$76.6K | 0.13% | 203 |
|
|
2021
Q4 | $442K | Sell |
3,265
-406
| -11% | -$48K | 0.11% | 194 |
|
|
2021
Q3 | $396K | Buy |
3,671
+35
| +1% | +$4K | 0.1% | 230 |
|
|
2021
Q2 | $429K | Sell |
3,636
-702
| -16% | -$79.1K | 0.1% | 218 |
|
|
2021
Q1 | $469K | Sell |
4,338
-229
| -5% | -$24.5K | 0.13% | 156 |
|
|
2020
Q4 | $489K | Sell |
4,567
-6,329
| -58% | -$608K | 0.14% | 158 |
|
|
2020
Q3 | $954K | Sell |
10,896
-21,753
| -67% | -$2.05M | 0.28% | 90 |
|
|
2020
Q2 | $3.21M | Sell |
32,649
-8,640
| -21% | -$761K | 0.86% | 29 |
|
|
2020
Q1 | $3.15M | Buy |
41,289
+26,215
| +174% | +$2.23M | 0.88% | 25 |
|
|
2019
Q4 | $1.35M | Sell |
15,074
-12,391
| -45% | -$1.03M | 0.25% | 97 |
|
|
2019
Q3 | $2.08M | Buy |
27,465
+4,197
| +18% | +$288K | 0.37% | 67 |
|
|
2019
Q2 | $1.69M | Buy |
23,268
+11,068
| +91% | +$870K | 0.3% | 75 |
|
|
2019
Q1 | $983K | Sell |
12,200
-36,125
| -75% | -$2.96M | 0.19% | 120 |
|
|
2018
Q4 | $4.45M | Buy |
48,325
+39,395
| +441% | +$3.46M | 0.8% | 24 |
|
|
2018
Q3 | $844K | Sell |
8,930
-2,736
| -23% | -$259K | 0.16% | 123 |
|
|
2018
Q2 | $1.08M | Sell |
11,666
-19,688
| -63% | -$1.92M | 0.18% | 122 |
|
|
2018
Q1 | $2.95M | Buy |
31,354
+5,281
| +20% | +$580K | 0.59% | 32 |
|
|
2017
Q4 | $2.52M | Sell |
26,073
-4,726
| -15% | -$445K | 0.43% | 40 |
|
|
2017
Q3 | $2.74M | Sell |
30,799
-9,710
| -24% | -$739K | 0.51% | 31 |
|
|
2017
Q2 | $2.94M | Sell |
40,509
-12,571
| -24% | -$845K | 0.63% | 32 |
|
|
2017
Q1 | $3.46M | Buy |
53,080
+46,110
| +662% | +$2.9M | 0.78% | 29 |
|
|
2016
Q4 | $436K | Sell |
6,970
-125,078
| -95% | -$7.63M | 0.09% | 167 |
|
|
2016
Q3 | $8.33M | Buy |
132,048
+124,908
| +1,749% | +$8.09M | 1.25% | 18 |
|
|
2016
Q2 | $442K | Sell |
7,140
-3,702
| -34% | -$226K | 0.07% | 138 |
|
|
2016
Q1 | $619K | Sell |
10,842
-13,287
| -55% | -$741K | 0.08% | 122 |
|
|
2015
Q4 | $1.43M | Buy |
24,129
+18,146
| +303% | +$1.05M | 0.2% | 69 |
|
|
2015
Q3 | $326K | Sell |
5,983
-463
| -7% | -$30.1K | 0.04% | 151 |
|
|
2015
Q2 | $433K | Sell |
6,446
-831
| -11% | -$54.3K | 0.05% | 150 |
|
|
2015
Q1 | $426K | Sell |
7,277
-2,309
| -24% | -$139K | 0.05% | 154 |
|
|
2014
Q4 | $627K | Buy |
+9,586
| New | +$604K | 0.09% | 126 |
|
Other funds holding ABBV
Exane Derivatives's ABBV Position: Q2 2022 in Review
Exane Derivatives reduced its AbbVie (ABBV) stake by 45% in Q2 2022, selling an estimated $187K and leaving 1,517 shares worth $232K. The position accounts for 0.13% of the portfolio, ranked #147.
Exane Derivatives first reported a position in ABBV in Q4 2014 and has held it in 31 quarters since. The position peaked at $8.33M in Q3 2016. 3,005 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.
- Exane Derivatives held 1,517 shares of AbbVie worth $232K as of Q2 2022.
- Exane Derivatives sold 1,221 AbbVie shares in Q2 2022, an estimated $187K.
- AbbVie made up 0.13% of Exane Derivatives's portfolio in Q2 2022, its #147 holding.
- Exane Derivatives first reported a position in AbbVie in Q4 2014 and has held it in 31 quarters since.
- Exane Derivatives's AbbVie position peaked at $8.33M in Q3 2016.
- 3,005 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.
Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.